![Andrew Dillin](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Andrew Dillin
Corporate Officer/Principal presso University of California, Berkeley
Profilo
Andrew Dillin is the founder of Proteostasis Therapeutics, Inc. (founded in 2006) and Mitobridge, Inc. (founded in 2013).
He is currently a Professor at the University of California, Berkeley.
Dr. Dillin earned a doctorate degree from the University of California, Berkeley.
Posizioni attive di Andrew Dillin
Società | Posizione | Inizio |
---|---|---|
University of California, Berkeley | Corporate Officer/Principal | - |
Precedenti posizioni note di Andrew Dillin
Società | Posizione | Fine |
---|---|---|
Mitobridge, Inc.
![]() Mitobridge, Inc. BiotechnologyHealth Technology Mitobridge, Inc. operates as a biopharmaceutical company. It focuses on the development and discovery of products for mitochondrial function. The firm also offers treatments for genetic, metabolic, and neurodegenerative disorders as well as diseases and conditions of aging. The company was founded by Kazumi Shiosaki, Andrew Dillin, Ronald M. Evans, Johan Auwerx and Robert H. Horvitz in October 2011 and is headquartered in Cambridge, MA. | Fondatore | - |
PROTEOSTASIS THERAPEUTICS, INC. | Fondatore | - |
Formazione di Andrew Dillin
University of California, Berkeley | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 2 |
---|---|
Proteostasis Therapeutics, Inc.
![]() Proteostasis Therapeutics, Inc. BiotechnologyHealth Technology Proteostasis Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It engages in the discovery and development of novel therapeutics to treat cystic fibrosis (CF) and other diseases caused by an imbalance in the proteostasis network. The company was founded by William Balch, Jeffery W. Kelly, Andrew Dillin, Richard I. Morimoto, Alfred Lewis Goldberg, Daniel Finley, Christopher T. Walsh, and Randall W. King in 2006 and is headquartered in Boston, MA. | Health Technology |
Mitobridge, Inc.
![]() Mitobridge, Inc. BiotechnologyHealth Technology Mitobridge, Inc. operates as a biopharmaceutical company. It focuses on the development and discovery of products for mitochondrial function. The firm also offers treatments for genetic, metabolic, and neurodegenerative disorders as well as diseases and conditions of aging. The company was founded by Kazumi Shiosaki, Andrew Dillin, Ronald M. Evans, Johan Auwerx and Robert H. Horvitz in October 2011 and is headquartered in Cambridge, MA. | Health Technology |
- Borsa valori
- Insiders
- Andrew Dillin